drugset
Drugs / Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)
last change Oct 2009 re-read 3 minutes ago

Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)

also known as (a) SCH 54031, PEGETRON (peginterferon alfa-2b) Powder for Solution · PEG

Protein / enzyme biologic

Developed for
chronic hepatitis C virus infection
Investigated by
Merck Sharp & Dohme LLC

Trials 1

today NCT00423800 · Ph 3
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00423800 Dec 2006 → Oct 2009 chronic hepatitis C virus infection Merck Sharp & Dohme LLC Terminated No outcome recorded Stop: Enrollment

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV) ClinicalTrials.gov intervention name — accepted as the source's own label NCT00423800 ↗
Known as (a) SCH 54031, PEGETRON (peginterferon alfa-2b) Powder for Solution “(a) SCH 54031, PEGETRON® (peginterferon alfa-2b) Powder for Solution” NCT00423800 ↗
Known as PEG “Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)” NCT00423800 ↗
Modality Protein / enzyme biologic “pegylated interferon alfa-2b” NCT00423800 ↗
Route Subcutaneous “pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous” NCT00423800 ↗